Cagrilintide + Semaglutide vs Tirzepatide
GLP-1 + amylin combination vs GLP-1/GIP dual.
| Attribute | Cagrilintide + Semaglutide CagriSema | Tirzepatide Dual GIP/GLP-1 receptor agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Amylin + GLP-1 combination weight-loss research | Dual-agonist weight loss research |
| In plain English | Two appetite-control switches in one protocol — GLP-1 for satiety, amylin for slower gastric emptying. | Tirzepatide is like semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies. |
| How it works | Semaglutide activates GLP-1 receptors for satiety and glucose control; cagrilintide engages amylin receptors to slow gastric emptying and reduce food intake. | Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying. |
| Researchers study | Obesity, weight maintenance, and combination metabolic therapy. | Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes. |
| Internet discussion | Discussed as the GLP-1/amylin answer to tirzepatide's GLP-1/GIP combination. | Often described as 'semaglutide on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules. |
Cagrilintide + Semaglutide
Amylin + GLP-1 combination weight-loss research
Two appetite-control switches in one protocol — GLP-1 for satiety, amylin for slower gastric emptying.
Semaglutide activates GLP-1 receptors for satiety and glucose control; cagrilintide engages amylin receptors to slow gastric emptying and reduce food intake.
Obesity, weight maintenance, and combination metabolic therapy.
Discussed as the GLP-1/amylin answer to tirzepatide's GLP-1/GIP combination.
Cagrilintide + Semaglutide (CagriSema) is the leading GLP-1 + amylin research combination for weight loss.
Tirzepatide
Dual-agonist weight loss research
Tirzepatide is like semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies.
Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying.
Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes.
Often described as 'semaglutide on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules.
Tirzepatide is a dual GLP-1/GIP agonist with strong clinical data for weight reduction and glycemic control.